Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:15 PM
Ignite Modification Date:
2025-12-24 @ 7:15 PM
NCT ID:
NCT00734903
Eligibility Criteria:
Inclusion Criteria:
* Female Veteran
* 18-65 years of age
* Meet DSM-IV criteria for current SUD with "current" defined as meeting SUD criteria per the DSM-IV and having used a substance within the 90 days prior to intake (to be able to accurately evaluate changes in their substance use from baseline)
* Plan to stay in the Boston area for the next 6 months
* Have a mailing address and live close enough to come to the hospital once weekly for treatment and/or assessment
* Able to complete the Statement of Informed Consent
* Willing to participate in all assessments and breathalyzer/urine testing
* Willing to provide a release of information such that study staff can contact her other providers as needed regarding any concerns during her participation
* Able to obtain medical clearance
* Willing to allow us to contact family and/or friends if participant loses contact with us
* Literate
* Not pregnant or planning to become pregnant
Exclusion Criteria:
* Any acute medical condition that would interfere with the participant's ability to participate in treatment, or would be of such severity as to affect the individual's psychological functioning (e.g., cancer)
* Current bipolar I disorder, schizophrenia or other psychotic disorders or mental retardation or organic mental disorder (determined by screening interview)
* Any clinical sign that the client is not sufficiently stable to participate in the treatment, such as client's treatment provider indicating that participation in the treatment would be contraindicated
* Dangerousness that would present a threat to other staff or other clients (e.g., history of recent assault)
* Client is mandated to treatment
* Psychopharmacologic treatment that is planned to change or likely to change substantively over the 3-month active treatment phase (with "substantive" defined as any addition of a new medication or major shift in dosage)
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT00734903
Study Brief:
Protocol Section:
NCT00734903